Gerresheimer Stock: Major Bank Pulls Back
Gerresheimer AG has faced a turbulent year, with its share price plummeting by over 61% since January. The company is now taking steps to restructure its business after a series of financial setbacks and declining investor confidence. Recent moves include a planned spin-off of its molded glass division and a sharp reduction in revenue expectations for 2025.
The company’s struggles became clearer as BNP Paribas, once a significant stakeholder, cut its voting rights from 5.54% to 0%. This reduction leaves Gerresheimer without any publicly identified institutional financial backing for 2025.
Operational challenges have also mounted. The firm issued three profit warnings this year, prompting Germany’s financial regulator, BaFin, to launch an investigation in September. Instead of the growth initially forecast, Gerresheimer now expects organic revenue to shrink by 2% to 4%. In response, management is pushing ahead with a restructuring plan. The molded glass business, a long-standing segment, may be spun off or sold entirely. This move aims to shore up the balance sheet and shift focus toward more profitable areas, such as the GLP-1 medication sector. Despite the downturn, the company still targets €200 million in revenue from GLP-1 products by next year.
Gerresheimer’s share collapse and financial warnings highlight the pressure on its leadership to stabilise operations. The planned sale of the molded glass unit and continued focus on GLP-1 medications will test whether the company can reverse its fortunes. With no major institutional support beyond BNP Paribas and an ongoing regulatory probe, the coming months will be critical for its recovery.
